The U.S. Food and Drug Administration could soon approve what would be the country's first prescription medicine derived from marijuana .
On Thursday, an FDA advisory panel unanimously recommended approving the drug called Epidiolex . A U.K. pharmaceutical company created it to treat rare and severe forms of epilepsy.
During clinical trials, patients given Epidiolex to help treat Dravet syndrome or Lennox-Gastaut syndrome saw the frequency of their seizures "significantly reduced," GW Pharmaceuticals said in a statement .
The medicine's active ingredient is cannabidiol — a chemical found in cannabis. Unlike medical marijuana, which contains a compound that can produce a high, cannabidiol isn't psychoactive.
The FDA will reportedly decide by the end of June if it'll approve Epidiolex.